NeuroSense's PrimeC Demonstrates Outstanding Effect On ALS Survival In Innovative iPSC Model
Portfolio Pulse from Benzinga Newsdesk
NeuroSense Therapeutics' drug, PrimeC, has shown significant improvement in the survival rate of induced motor neurons in an in vitro study. The study was conducted in collaboration with the University of Southern California's Ichida Stem Cell Lab, using induced pluripotent stem cells (iPSCs) generated from people living with ALS. In a previous independent study, PrimeC outperformed several other ALS drugs in development and two ALS FDA approved drugs.
October 04, 2023 | 1:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
NeuroSense's PrimeC has shown promising results in ALS treatment, which could potentially lead to increased interest and investment in the company.
The positive results from the study of PrimeC could potentially lead to increased interest in NeuroSense Therapeutics. This could result in increased investment in the company, potentially leading to a rise in the company's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100